REXULTI

Use the June 2026 product-specific form; filenames still contain 2025. The foundation sets eligibility and Otsuka America Pharmaceutical, Inc. has no role in its decisions. REXULTI and MAINTENA forms show 8 a.m.-6 p.m. on early pages and 8 a.m.-8 p.m. on later pages; confirm service hours. Only these three reviewed medicines are mapped here.

Distinct patient/caregiver portal linked by OPAF Care Connect. Public login shell retrieved; no authentication or application was tested. Product scope is limited to the three reviewed current forms.

Distinct prescriber portal for applications on behalf of patients, as described by OPAF Care Connect. Public login shell retrieved; no authentication or application was tested.

Published question line for the Otsuka America Pharmaceutical, Inc. REXULTI savings program. Commercial coverage and product-specific terms apply. OPAF assistance is a separate foundation process.

Current linked June 2026 form provides this separate reimbursement question line and mailing destination. It requires the reimbursement form and specified insurance/card, prescription and receipt evidence. The program also discusses eligible generic antidepressants, but this batch does not infer or import a generic medicine roster. Reimbursement remains subject to review.

The current REXULTI commercial-insurance content publishes this Otsuka Connect nurse contact when the Integrated Pharmacy Network finder has no result. This route is qualified to that pharmacy-navigation context; it is not used to infer all Otsuka medicine coverage, PAP intake, an enrollment email or reimbursement processing.